Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.

Delaugerre C, Teglas JP, Treluyer JM, Vaz P, Jullien V, Veber F, Rouzioux C, Chaix ML, Blanche S.

J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1269-75.

PMID:
15385734
2.

Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.

Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J; HIV-NAT 017 Study Team.

Pediatr Infect Dis J. 2008 Jul;27(7):623-8. doi: 10.1097/INF.0b013e31816b4539.

PMID:
18520443
3.

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H; Groupe d' Epidémiologie Clinique du SIDA en Aquitaine.

Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32.

4.

The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.

J Clin Virol. 2007 Feb;38(2):131-8. Epub 2007 Jan 4.

PMID:
17208042
5.

[Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].

Brunet-François C, Taieb A, Masquelier B, Le Moing V, Lewden C, Dellamonica P, Cuzin L, Allavena C, Spire B, Chêne G, Raffi F; Groupe d'Etude Aproco-Copilote (ANRS C08).

Med Mal Infect. 2007 Mar;37(3):172-7. Epub 2007 Jan 17. French.

PMID:
17239554
6.

Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E; Spanish Collaborative Group on HIV Infection in Children.

Pediatr Infect Dis J. 2005 Oct;24(10):867-73.

PMID:
16220083
7.

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Rudin C, Burri M, Shen Y, Rode R, Nadal D; Pediatric Infectious Disease Group of Switzerland; Swiss Mother and Child HIV Cohort Study (MoCHiV).

Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.

PMID:
18382386
8.

The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.

Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Hoetelmans R, Nauwelaers D, Lazzarin A.

Antivir Ther. 2004 Aug;9(4):537-43.

PMID:
15456085
9.

Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.

King MS, Rode R, Cohen-Codar I, Calvez V, Marcelin AG, Hanna GJ, Kempf DJ.

Antimicrob Agents Chemother. 2007 Sep;51(9):3067-74. Epub 2007 Jun 18. Erratum in: Antimicrob Agents Chemother. 2008 Feb;52(2):811.

10.

Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.

Resino S, Bellón JM, Ramos JT, Navarro ML, Martín-Fontelos P, Cabrero E, Muñoz-Fernández MA.

Pediatr Infect Dis J. 2004 Oct;23(10):923-30.

PMID:
15602192
11.
12.
13.

Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.

Frange P, Briand N, Avettand-fenoel V, Veber F, Moshous D, Mahlaoui N, Rouzioux C, Blanche S, Chaix ML.

Pediatr Infect Dis J. 2011 Aug;30(8):684-8. doi: 10.1097/INF.0b013e31821752d6.

PMID:
21427626
14.

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.

Bongiovanni M, Bini T, Adorni F, Meraviglia P, Capetti A, Tordato F, Cicconi P, Chiesa E, Cordier L, Cargnel A, Landonio S, Rusconi S, d'Arminio Monforte A.

Antivir Ther. 2003 Jun;8(3):209-14.

PMID:
12924537
15.

Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.

Rudin C, Wolbers M, Nadal D, Rickenbach M, Bucher HC; Pediatric Infectious Disease Group of Switzerland (PIGS); Swiss Mother and Child HIV Cohort Study (MoCHiV).

Arch Dis Child. 2010 Jun;95(6):478-81. doi: 10.1136/adc.2009.169375.

16.

Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.

Barreiro P, Camino N, de Mendoza C, Valer L, Núñez M, Martín-Carbonero L, González-Lahoz J, Soriano V.

Int J Antimicrob Agents. 2002 Dec;20(6):438-43.

PMID:
12458138
18.

Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

Verweel G, Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der Knaap LC, Driessen G, de Groot R, Hartwig NG.

Antivir Ther. 2007;12(4):453-8.

PMID:
17668553
19.

Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced Brazilian children receiving highly active antiretroviral therapy containing lopinavir-ritonavir.

Machado DM, Gouvêa Ade F, Cardoso MR, Beltrão SV, Cunegundes KS, Bononi F, Almeida F, Cavalheiro K, Angelis DS, Succi RC.

Braz J Infect Dis. 2007 Feb;11(1):16-9.

20.

Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.

Larrú B, Resino S, Bellón JM, de José MI, Fortuny C, Navarro ML, Gurbindo MD, Ramos JT, Soler Palacín P, Léon JA, Asensi M, Mellado MJ, Muñoz-Fernández MA.

J Antimicrob Chemother. 2008 Jan;61(1):183-90. Epub 2007 Nov 19.

PMID:
18025025

Supplemental Content

Support Center